- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04973163
Uno studio per testare diverse dosi di BI 1823911 da solo e in combinazione con altri medicinali in persone con diversi tipi di cancro avanzato con mutazione KRAS
Uno studio di fase Ia/Ib, in aperto, multicentrico di escalation ed espansione della dose per studiare la sicurezza, la farmacocinetica e l'efficacia preliminare di BI 1823911 come monoterapia e in combinazione con altre terapie antitumorali in pazienti con tumori solidi avanzati o metastatici che esprimono Mutazione KRAS G12C
This study is open to adults with different types of advanced or metastatic cancer (including lung cancer, colorectal cancer, pancreatic cancer, and bile duct cancer). This study is for people for whom previous treatment was not successful or no treatment exists.
People who have a tumour with a KRAS mutation can participate in the study. A KRAS mutation makes tumours grow faster. BI 1823911 and BI 1701963 are medicines that may turn off KRAS, each in a different way. In this study, BI 1823911 is given to people for the first time.
The purpose of this study is to find the highest dose of BI 1823911 that people can tolerate when taken alone and together with BI 1701963. The most suitable dose is used to find out whether BI 1823911 alone and in combination with BI 1701963 can make tumours shrink.
Participants can stay in the study as long as they benefit from treatment and can tolerate it.
During this time, participants take tablets of BI 1823911 alone or in combination with BI 1701963 once a day. The doctors regularly monitor the size of the tumour. Doctors also regularly record any unwanted effects and check participant's health.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Anderlecht/Brussels-Capital, Belgio, 1070
- Brussels - HOSP Jules Bordet
-
Edegem/Antwerpen, Belgio, 2650
- Universitair Ziekenhuis Antwerpen
-
Gent/Oost-Vlaanderen, Belgio, 9000
- Universitair Ziekenhuis Gent
-
Leuven/Vlaams-Brabant, Belgio, 3000
- UZ Leuven
-
-
-
-
-
Manchester, Regno Unito, M20 4BX
- The Christie
-
-
-
-
-
Barcelona, Spagna, 08035
- Hospital Universitari Vall d'Hebron
-
-
-
-
New York
-
New York, New York, Stati Uniti, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75230
- Sarah Cannon Research Institute at Mary Crowley
-
Houston, Texas, Stati Uniti, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Pathologically confirmed diagnosis of locally advanced or metastatic solid tumours, e.g. adenocarcinoma of the lung, colorectal cancer, pancreatic cancer or cholangiocarcinoma. Non-small cell lung cancer (NSCLC) patients with mixed histology are eligible if adenocarcinoma is the predominant histology.
-
Documented disease progression despite appropriate prior standard therapies or for whom no standard therapy exists for their tumour type and disease stage.
-
KRAS mutation status: Kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation in tumour tissue or blood based on previously performed local testing using a validated test.
-
Provision of archival tumour tissue, if available, to confirm retrospectively KRAS G12C mutation status and for biomarker assessment.
-
At least one target lesion that can be measured per Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (radiated lesions do not qualify as target lesions). In patients who only have one target lesion, and a biopsy of the lesion is required, the baseline imaging must be performed before the biopsy or at the earliest two weeks after the biopsy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Adequate organ function as follows:
- Absolute neutrophil count (ANC) ≥1.5 x 10^9/L (equivalent values: ≥ 1.5 x 10³/μL or ≥ 1500/mm³); hemoglobin ≥9.0 g/dL (equivalent values: ≥ 90 g/L or ≥ 5.6 mmol/L); platelets ≥100 x 10^9/L (equivalent values: ≥ 100 x 10³/μL or ≥ 100 x 10³/mm³) without the use of haematopoietic growth factors.
- Total bilirubin ≤1.5 times the upper limit of normal (ULN), or ≤4 x ULN for patients who are known to have Gilbert's syndrome.
- Creatinine ≤1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if concurrent creatinine clearance ≥50 mL/min (equivalent value: 0.84mL/s) (measured or calculated by Cockcroft-Gault formula).
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN, for patients with liver metastases ≤5 x ULN.
-
Age ≥18 years of age, or over the legal age of consent as required by local legislation.
Further inclusion criteria apply.
Exclusion Criteria:
- Previous anticancer chemotherapy within 3 weeks of the first administration of trial drug. Previous anticancer hormonal treatment or anticancer immunotherapy within 2 weeks of the first administration of trial drug.
- Previous treatment with Rat Sarcoma (RAS), Mitogen-activated protein kinase (MAPK) or Son of sevenless 1 (SOS1) targeting agents (only for monotherapy Parts A, B, and C).
- Radiotherapy within 2 weeks prior to start of treatment, provided recovery from related toxicity.
- Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of treatment or planned during the projected course of the trial, e.g. hip replacement.
- Previous treatment with any investigational agent(s) or targeted treatment within 28 days prior to start of treatment or 5 half-lives, whichever is shorter.
- Known history of hypersensitivity to any of the excipients of BI 1823911 tablets, or any contraindication to Midazolam (for Monotherapy Part B only).
- History or presence of cardiovascular abnormalities such as congestive heart failure New York Heart Association (NYHA) classification of ≥3, unstable angina or poorly controlled arrhythmia which are considered clinically relevant by the Investigator. Myocardial infarction within 6 months prior to start of treatment. Uncontrolled hypertension defined as: Blood pressure (BP) measured in a rested and relaxed condition, where systolic BP >=140 mmHg, or diastolic BP >= 90 mmHg, with or without medication.
- Left ventricular ejection fraction (LVEF) <50%. Further exclusion criteria apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Monotherapy Arm
Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C). |
BI 1823911 Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm |
|
Sperimentale: Combination Therapy Arm
Will be started after confirmation of safety in the Monotherapy Arm. Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C). |
BI 1823911 BI 1701963 |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Dose escalation (Part A) - Monotherapy and combination therapy: Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period for BI 1823911 in monotherapy and in each combination
Lasso di tempo: up to 28 days
|
DLTs are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
up to 28 days
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR) defined as best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR)
Lasso di tempo: up to 39 months
|
BOR is determined according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. |
up to 39 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Escalation della dose (Parte A) - Monoterapia e terapia di combinazione: numero di pazienti che hanno manifestato DLT durante tutti i cicli di trattamento per BI 1823911 in monoterapia e in ciascuna combinazione
Lasso di tempo: fino a 39 mesi
|
fino a 39 mesi
|
|
|
Tutte le parti dello studio: numero di pazienti con eventi avversi durante il periodo di trattamento attivo
Lasso di tempo: fino a 39 mesi
|
fino a 39 mesi
|
|
|
Tutte le parti dello studio, BI 1823911: Concentrazione massima (Cmax)
Lasso di tempo: fino a 24 ore
|
fino a 24 ore
|
|
|
Tutte le parti dello studio, BI 1823911: concentrazione allo stato stazionario (Css)
Lasso di tempo: fino a 24 ore
|
fino a 24 ore
|
|
|
Tutte le parti dello studio, BI 1823911: Area sotto la curva della concentrazione plasmatica nel tempo dal tempo zero al tempo t (AUCτ)
Lasso di tempo: fino a 24 ore
|
fino a 24 ore
|
|
|
Tutte le parti dello studio, BI 1823911: Area sotto la curva della concentrazione plasmatica nel tempo allo stato stazionario (AUCss)
Lasso di tempo: fino a 24 ore
|
fino a 24 ore
|
|
|
Tutte le parti dello studio, BI 1701963: Concentrazione massima (Cmax)
Lasso di tempo: fino a 24 ore
|
fino a 24 ore
|
|
|
Tutte le parti dello studio, BI 1701963: concentrazione allo stato stazionario (Css)
Lasso di tempo: fino a 24 ore
|
fino a 24 ore
|
|
|
Tutte le parti dello studio, BI 1701963: Area sotto la curva della concentrazione plasmatica nel tempo dal tempo zero al tempo t (AUCτ)
Lasso di tempo: fino a 24 ore
|
fino a 24 ore
|
|
|
Tutte le parti dello studio, BI 1701963: Area sotto la curva della concentrazione plasmatica nel tempo allo stato stazionario (AUCss)
Lasso di tempo: fino a 24 ore
|
fino a 24 ore
|
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR)
Lasso di tempo: up to 39 months
|
OR is defined as best overall response (BOR) of complete response (CR) or partial response (PR), both regardless of confirmation. BOR is determined according to RECIST version 1.1. BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Duration of OR
Lasso di tempo: up to 39 months
|
Duration of OR is defined as the time from first documented CR or PR until disease progression or death (whichever occurs first) among patients with OR. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Tumour shrinkage (in millimetres)
Lasso di tempo: up to 39 months
|
Tumour shrinkage is defined as the difference between the minimum post-baseline sum of diameters of target lesions (longest for non-nodal lesions, short axis for nodal lesions) and the baseline sum of longest diameters of the same set of target lesions. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Progression-free survival (PFS) rate
Lasso di tempo: at month 6
|
PFS is defined as the time from first treatment administration until tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs earlier. |
at month 6
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 1472-0001
- 2021-000460-29 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).
For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .